Table 4.

Genotypic distribution for IL-28B gene polymorphism when chronic HCV patients (group 1) were compared to individuals with liver cirrhosis and HCC carriers (groups “2+3”).

SNPs	Genotype/allele distribution	(Chronic HCV) n = 518	(Cirr + HCC) n = 160	OR (95% C.I.)	χ ²	P value
rs8105790				1.049 (0.815–1.350)	0.14	0.710
	CC	119 (23%)	40 (25%)
	CT	216 (42%)	64 (40%)
	TT	183 (35%)	56 (35%)
	C	454 (43.8%)	144 (45%)
	T	582 (56.2%)	176 (55%)
	CC + CT versus TT			1.014 (0.700–1.471)	0.01	0.939
	CC versus CT + TT			0.895 (0.592–1.351)	0.28	0.596
rs8099917				0.986 (0.739–1.315)	0.01	0.923
	GG	80 (15.4%)	24 (15%)
	GT	105 (20.3%)	33 (20.6%)
	TT	333 (64.3%)	103 (64.4%)
	G	265 (25.6%)	81 (25.3%)
	T	771 (74.4%)	239 (74.7%)
	GG + GT versus TT			0.996 (0.688–1.442)	0	0.983
	GG versus GT + TT			1.035 (0.631–1.698)	0.02	0.891
rs7248668				1.204 (0.912–1.590)	1.72	0.190
	AA	65 (12.5%)	29 (18.1%)
	AG	136 (26.3%)	36 (22.5%)
	GG	317 (61.2%)	95 (59.4%)
	A	266 (25.7%)	94 (29.4%)
	G	770 (74.3%)	226 (70.6%)
	AA + AG versus GG			1.079 (0.752–1.549)	0.17	0.679
	AA versus AG + GG			0.648 (0.402–1.046)	3.18	0.074
rs12979860				1.167 (0.903–1.507)	1.39	0.238
	TT	50 (9.7%)	23 (14.4%)
	CT	283 (54.6%)	84 (52.5%)
	CC	185 (35.7%)	53 (33.1%)
	T	383 (37%)	130 (40.6%)
	C	653 (63%)	190 (59.4%)
	TT + CT versus CC			1.122 (0.771–1.632)	0.36	0.548
	TT versus CT + CC			0.636 (0.375–1.080)	2.84	0.092
rs12980275				0.929 (0.716–1.206)	0.3	0.580
	GG	69 (13%)	20 (12.5%)
	AG	252 (49%)	75 (46.9%)
	AA	197 (38%)	65 (40.6%)
	G	390 (38%)	115 (36%)
	A	646 (62%)	205 (64%)
	GG + AG versus AA			0.897 (0.625–1.288)	0.35	0.555
	GG versus AG + AA			1.076 (0.631–1.832)	0.07	0.788

Risk allele marked in BOLD letter.